Healthcare was one sector that did not fully participate in the recent stockmarket rally and finished the first quarter as the worst performer in the S&P 500 index, writes Legg Mason's Evan Bauman.
Americans are an optimistic bunch by nature. However, talk of secular stagnation, declining opportunities and faltering growth have become the topics de jour.
Biotech has fallen
It is hard to think of the 'positives' of an ageing population in the UK, writes Lawrence Gosling.
Tom Delic, assistant fund manager at Seneca Investment Managers explores the demographic trends - from opportunities in tech to wealth management - that are available for investors to take advantage of
The Merchants trust's Simon Gergel explains why investing in one of the UK's biggest healthcare stocks - GlaxoSmithKline - is not as simple as many investors envisage
Hardeep Tawakley takes a closer look at the evolution of specialist funds and speaks to buyers about their favourite offerings.